FDA Alerts

FDA grants priority review for eosinophilic esophagitis treatment

The U.S. Food and Drug Administration has accepted a new drug application (NDA) for review and granted priority review for the investigational therapy budesonide oral suspension (TAK-721; Takeda Pharmaceutical Company Limited) for eosinophilic esophagitis (EoE), according to a press release. There is currently no FDA-approved treatment for EoE. TAK-721 previously...